Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
ARCT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.39 - $45.00
Previous CloseN/A
Volume109.32K
Average Volume (3M)420.47K
Market Cap
$314.05M
Enterprise Value$365.35M
Total Cash (Recent Filing)$22.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.88
Next Earnings
May 12, 2025EPS Estimate
-1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.00
Shares Outstanding27,119,823
10 Day Avg. Volume344,007
30 Day Avg. Volume420,467
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.29
Price to Cash Flow (P/CF)-307.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.40
Enterprise Value/Ebitda-5.24
Forecast
1Y Price Target
$69.29Price Target Upside554.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Funding And Financial SupportThe ARCT-2304 mRNA vaccine candidate against the H5N1 virus is fully-funded by BARDA, providing financial support for its development.
Market PotentialThe LunairCF trial is targeting a patient segment that represents a valuable market, especially those ineligible for existing CF treatments.
Research And DevelopmentArcturus announced that interim data from its Phase 2 study of ARCT-032 for cystic fibrosis are on target, indicating potential effectiveness in treating the disease.
Bears Say
Operational ChallengesDistribution partner Meiji has faced initial headwinds and reported a significant operating profit loss due to increased Kostaive inventory write downs.
Price Target And Market OutlookThe price target for ARCT has been lowered from $70 to $65.
Revenue And Financial PerformanceFY24 revenue of $152mm was below expectations, representing a ~9% year-over-year decline mainly due to lower CSL milestones.
---
Ownership Overview
8.44% Insiders
30.79% Mutual Funds
0.30% Other Institutional Investors
39.02% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $11.39 and its highest was $45.00 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Arcturus Therapeutics’s market cap is $314.05M.
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s upcoming earnings report date is May 12, 2025 which is in 40 days.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on Mar 06, 2025. The company reported -$1.11 earnings per share for the quarter, missing the consensus estimate of -$0.548 by -$0.562.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics does not currently pay dividends.
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -1.1.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 27,119,823 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$1.11 in its last earnings report, missing expectations of -$0.548. Following the earnings report the stock price went down -8.892%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Currently, no hedge funds are holding shares in ARCT
---
Arcturus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$69.29 (554.30% Upside)
$69.29 (554.30% Upside)
Blogger Sentiment
Bullish
ARCT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 296.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.64%
12-Months-Change
Fundamentals
Return on Equity
-31.16%
Trailing 12-Months
Asset Growth
-19.87%
Trailing 12-Months
Company Description
Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
---
ARCT Company Deck
---
ARCT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook for Arcturus Therapeutics. While there were significant achievements such as the European approval of KOSTAIVE and progress in various clinical programs, these were offset by financial challenges including decreased revenue and increased net loss. The company's strong cash position and expected cash runway provide some reassurance.Read More>---
ARCT Stock 12 Month Forecast
Average Price Target
$69.29
▲(554.30% Upside)
Technical Analysis
Best Analysts Covering ARCT
1 Year
1 Year Success Rate
3/20 ratings generated profit
1 Year Average Return
-31.42%
reiterated a buy rating 26 days ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 15.00% of your transactions generating a profit, with an average return of -31.42% per trade.
---